NEWS
THE
11th ASIA PASIFIC LEAGUE of ASSOCITIONS FOR RHEUMATOLOGY
(APLAR)
Congress was held on
the beautiful island of Jeju, Korea, from September
11-15, 2004. About 1,500 delegates, mostly from the Asia
Pacific region, met to discuss a broad range of topics
in the musculoskeletal diseases. The program was
extremely well organised with keynote addresses,
parallel seminars and workshops, an allied health
professional symposium, and a clinical review course.
About 80 oral free papers were presented and more than
400 posters were in a well displayed area.
There was workshop has been conducted to discuss about
JD Protocol. You will find below three abstracts about
Treatment with the Step-down Bridge for autoimmune
diseases:
- Seven-years
Outcome of Rheumatoid Factor Positive Rheumatoid
Arthritis after Treatment with the Step-down Bridge
Intravenous and Oral Combination of 5
Immunosuppressants.
[
download ]
- Seven-years
Outcome of Biopsy Proven Lupus Nephritis after
Treatment with the Step-down Bridge Intravenous and
Oral Combination of 5 Immunosuppressants.
[
download ]
- Six-years
Outcome of NSAID-Refractory Ankylosing Spondylitis
After Treatment with the
Step-down Bridge Intravenous and Oral Combination of
5 Immunosuppressants.
[
download ]
Email This Page
Print
This Page
|
|
| |
NEWS & EVENTS
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
16.11.2005
MabThera – a unique approach providing lasting
benefits for patients with rheumatoid arthritis
Comprehensive long-term clinical success achieved in
difficult-to-treat patients following just two
administrations, two weeks apart
›
more
|
|
 |
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.09.2005
Roche files first rheumatoid arthritis indication for
MabThera in Europe
MabThera: a medicine used to treat non-Hodgkin's
lymphoma
MabThera delivers significant and sustained relief from
symptoms in patients with difficult-to-treat rheumatoid
arthritis.
›
more
|
|
|
|
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.04.2005
MabThera significantly improves symptoms in patients
with rheumatoid arthritis who inadequately responded to
anti-TNFα therapies
Third large randomised trial to evaluate efficacy and
safety of MabThera in RA
Roche, Genentech and Biogen Idec announced today that
REFLEX1, a pivotal Phase III study of MabThera (rituximab), successfully met its
primary endpoint in the group of patients with the most difficult-to-treat
rheumatoid arthritis (RA).
›
more
|
|
 |
Website Partner
 |
Bahasa 
